4.96

0.40% -0.02

After Hours: 4.95 -0.010 -0.20%

Maravai Lifesciences Holdings Inc (MRVI)

Overview News Price History Option Chain Financials Why MRVI Down? Discussions Forecast

Maravai Lifesciences Holdings Inc stock is traded at $4.96, with a volume of 2.92M. It is down -0.40% in the last 24 hours and up +19.52% over the past month. Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.

Previous Close:

$4.98

Open:

$5.02

24h Volume:

2.92M

Relative Volume:

1.22

Market Cap:

$731.63M

Revenue:

$204.73M

Net Income/Loss:

$-184.29M

P/E Ratio:

-6.8641

EPS:

-0.7226

Net Cash Flow:

$-51.87M

1W Performance:

-1.59%

1M Performance:

+19.52%

6M Performance:

+35.15%

1Y Performance:

+132.86%

1-Day Range:

$4.8514

$5.065

1-Week Range:

$4.8514

$5.30

52-Week Range:

$1.99

$5.30

Maravai Lifesciences Holdings Inc Stock (MRVI) Company Profile

Name

Maravai Lifesciences Holdings Inc

Sector

Healthcare (1104)

Industry

Biotechnology (621)

Phone

(858) 546-0004

Address

10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO

Employee

416

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

MRVI's Discussions on Twitter

Compare MRVI vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MRVI Maravai Lifesciences Holdings Inc	4.96	734.58M	204.73M	-184.29M	-51.87M	-0.7226
VRTX Vertex Pharmaceuticals Inc	450.46	112.92B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	614.98	64.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	884.20	55.57B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	287.80	37.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	160.06	32.71B	742.00K	-1.37B	-1.07B	-7.0731

Maravai Lifesciences Holdings Inc Stock (MRVI) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Downgrade	Robert W. Baird	Outperform → Neutral
Dec-19-24	Initiated	Guggenheim	Neutral
Dec-05-24	Downgrade	Goldman	Neutral → Sell
Nov-14-24	Initiated	Wolfe Research	Peer Perform
Nov-08-24	Downgrade	William Blair	Outperform → Mkt Perform
Aug-28-24	Initiated	Wells Fargo	Overweight
Aug-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-10-24	Initiated	Craig Hallum	Buy
Dec-12-23	Upgrade	BofA Securities	Neutral → Buy
Aug-08-23	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
May-23-23	Downgrade	Credit Suisse	Outperform → Neutral
May-09-23	Downgrade	Goldman	Buy → Neutral
Jan-05-23	Downgrade	UBS	Buy → Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-07-22	Initiated	RBC Capital Mkts	Outperform
Nov-03-22	Downgrade	BofA Securities	Buy → Neutral
Aug-25-22	Initiated	Credit Suisse	Outperform
Aug-05-21	Resumed	Credit Suisse	Outperform
Dec-16-20	Initiated	KeyBanc Capital Markets	Overweight
Dec-15-20	Initiated	BofA Securities	Buy
Dec-15-20	Initiated	Credit Suisse	Outperform
Dec-15-20	Initiated	Goldman	Buy
Dec-15-20	Initiated	Jefferies	Buy
Dec-15-20	Initiated	Robert W. Baird	Outperform
Dec-15-20	Initiated	Stifel	Buy
Dec-15-20	Initiated	William Blair	Outperform
Dec-14-20	Initiated	UBS	Buy

View All

Maravai Lifesciences Holdings Inc Stock (MRVI) Latest News

Jun 11, 2026